Cargando…
The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases
Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), currently affect more than 6 million people in the United States. Unfortunately, there are no treatments that slow or prevent disease developm...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627573/ https://www.ncbi.nlm.nih.gov/pubmed/31234550 http://dx.doi.org/10.3390/ijms20123056 |
_version_ | 1783434768114778112 |
---|---|
author | Maher, Pamela |
author_facet | Maher, Pamela |
author_sort | Maher, Pamela |
collection | PubMed |
description | Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), currently affect more than 6 million people in the United States. Unfortunately, there are no treatments that slow or prevent disease development and progression. Regardless of the underlying cause of the disorder, age is the strongest risk factor for developing these maladies, suggesting that changes that occur in the aging brain put it at increased risk for neurodegenerative disease development. Moreover, since there are a number of different changes that occur in the aging brain, it is unlikely that targeting a single change is going to be effective for disease treatment. Thus, compounds that have multiple biological activities that can impact the various age-associated changes in the brain that contribute to neurodegenerative disease development and progression are needed. The plant-derived flavonoids have a wide range of activities that could make them particularly effective for blocking the age-associated toxicity pathways associated with neurodegenerative diseases. In this review, the evidence for beneficial effects of multiple flavonoids in models of AD, PD, HD, and ALS is presented and common mechanisms of action are identified. Overall, the preclinical data strongly support further investigation of specific flavonoids for the treatment of neurodegenerative diseases. |
format | Online Article Text |
id | pubmed-6627573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-66275732019-07-23 The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases Maher, Pamela Int J Mol Sci Review Neurodegenerative diseases, including Alzheimer’s disease (AD), Parkinson’s disease (PD), Huntington’s disease (HD), and amyotrophic lateral sclerosis (ALS), currently affect more than 6 million people in the United States. Unfortunately, there are no treatments that slow or prevent disease development and progression. Regardless of the underlying cause of the disorder, age is the strongest risk factor for developing these maladies, suggesting that changes that occur in the aging brain put it at increased risk for neurodegenerative disease development. Moreover, since there are a number of different changes that occur in the aging brain, it is unlikely that targeting a single change is going to be effective for disease treatment. Thus, compounds that have multiple biological activities that can impact the various age-associated changes in the brain that contribute to neurodegenerative disease development and progression are needed. The plant-derived flavonoids have a wide range of activities that could make them particularly effective for blocking the age-associated toxicity pathways associated with neurodegenerative diseases. In this review, the evidence for beneficial effects of multiple flavonoids in models of AD, PD, HD, and ALS is presented and common mechanisms of action are identified. Overall, the preclinical data strongly support further investigation of specific flavonoids for the treatment of neurodegenerative diseases. MDPI 2019-06-22 /pmc/articles/PMC6627573/ /pubmed/31234550 http://dx.doi.org/10.3390/ijms20123056 Text en © 2019 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Maher, Pamela The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases |
title | The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases |
title_full | The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases |
title_fullStr | The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases |
title_full_unstemmed | The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases |
title_short | The Potential of Flavonoids for the Treatment of Neurodegenerative Diseases |
title_sort | potential of flavonoids for the treatment of neurodegenerative diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627573/ https://www.ncbi.nlm.nih.gov/pubmed/31234550 http://dx.doi.org/10.3390/ijms20123056 |
work_keys_str_mv | AT maherpamela thepotentialofflavonoidsforthetreatmentofneurodegenerativediseases AT maherpamela potentialofflavonoidsforthetreatmentofneurodegenerativediseases |